Subscribe: pubmed: Blood Reviews [Jour]
http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=0AdWssYm5a7GW6jJuaYIan2USBcvx95w25nA0ycurLW
Preview: pubmed: Blood Reviews [Jour]

pubmed: Blood Reviews [Jour]



NCBI: db=pubmed; Term="Blood Reviews"[Jour]



 



Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations.

Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations.

Blood Rev. 2016 Sep 17;

Authors: Pagano L, Busca A, Candoni A, Cattaneo C, Cesaro S, Fanci R, Nadali G, Potenza L, Russo D, Tumbarello M, Nosari A, Aversa F, SEIFEM (Sorveglianza Epidemiologica Infezioni Fungine nelle Emopatie Maligne) Group., Other Authors:

Abstract
Invasive fungal infections (IFIs) are an important cause of morbidity and mortality in immunocompromised patients. Patients with hematological malignancies undergoing conventional chemotherapy, autologous or allogeneic hematopoietic stem cell transplantation are considered at high risk, and Aspergillus spp. represents the most frequently isolated micro-organisms. In the last years, attention has also been focused on other rare molds (e.g., Zygomycetes, Fusarium spp.) responsible for devastating clinical manifestations. The extensive use of antifungal prophylaxis has reduced the infections from yeasts (e.g., candidemia) even though they are still associated with high mortality rates. This paper analyzes concurrent multiple predisposing factors that could favor the onset of fungal infections. Although neutropenia is common to almost all hematologic patients, other factors play a key role in specific patients, in particular in patients with AML or allogeneic HSCT recipients. Defining those patients at higher risk of IFIs may help to design the most appropriate diagnostic work-up and antifungal strategy.

PMID: 27682882 [PubMed - as supplied by publisher]